Direct-to-Consumer Surgery: Non-invasive liposuction for the masses

Not so very long ago, reimbursement was king in the world of medical devices. But the overnight success of injectible anti-wrinkle drug Botox signalled a change in the market. Now device companies developing liposuction alternatives hope to repeat that success, perhaps most importantly, in building their businesses outside of traditional reimbursement circles with a largely consumer-driven or self-pay market with new devices for cosmetic surgery applications.

Not so very long ago, reimbursement was king in the world of medical devices. Without reimbursement, there was no market, particularly for devices that had any degree of invasiveness to them. For that reason, if companies with surgical or even minimally invasive devices dreamed of one day selling to the virtually unlimited consumer market, they took the high road to the marketplace, by targeting a dire, and reimbursable, medical need first. Thus, Allergan Inc. , which had a multi-focal lens that could help the middle aged see both near and far without reading glasses, positioned its implantable device for the cataract market. Medtronic Inc. , looking into the market for obesity devices, got its electrical stimulation device approved for gastroparesis, an uncommon but horrendous disorder that causes frequent vomiting. (See "Obesity: Supersized Medical Device Market Also see "Obesity: Super-Sized Medical Device Market " - Medtech Insight, 1 March, 2003.) And injectable anti-wrinkle drug Botox (botulinum toxin) first entered the market as a therapy for a rare facial twitching disorder. But things are changing, and it was perhaps the overnight success of Botox that first signaled this shift.

Botox has boomed since its introduction in 2000; there were 1.6 million Botox injections in 2002, up 4% over the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By 

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.